Scottish Patients Denied Access to Life-Saving Cancer Treatments due to Funding Shortfalls

Strategic Insights -

Kevin Wemyss, a 47-year-old data network engineer from Inverness, was told he had a rare and aggressive form of liver cancer, cholangiocarcinoma, by a Scottish NHS nurse before the biopsy was even confirmed. The nurse informed him that there were limited treatment options available, despite new targeted drugs being approved for use in England. Wemyss is one of the over 200 patients in Scotland diagnosed with cholangiocarcinoma every year who cannot access these life-saving treatments due to funding shortfalls.

Key Takeaways:

  • Over 200 patients in Scotland are diagnosed with cholangiocarcinoma every year, and most cannot access new, targeted treatments despite them being approved in England.
  • Funding for molecular testing to determine the best treatment for patients has not been allocated by the Scottish government, leaving many without options.
  • Clinicians and scientists in Scotland are advocating for the use of new treatments for cholangiocarcinoma, which are currently not available due to funding constraints.
  • Patients like Kevin Wemyss are being forced to seek private consultations and treatments in England, where the necessary testing and treatments are available.
  • The Scottish government acknowledges the issues and is working to develop a more sustainable funding approach for genomic testing, but the delays and lack of access are having a devastating impact on patient care and outcomes.
  • Kevin Wemyss's biopsy confirmed the diagnosis in February, and he is now receiving generic chemotherapy in Scotland, which has shrunk the tumors, but he hopes to join a drugs trial in England.
  • Jenni Minto, the public health minister, has acknowledged the concerns and is committed to addressing the gaps in access to genomic testing, recognizing the real impact on patient care and outcomes.

Statistics:

  • Over 200 patients in Scotland are diagnosed with cholangiocarcinoma every year (no specific year mentioned).
  • Cancer Research UK places the proportion of patients alive five years after diagnosis with cholangiocarcinoma at just 5%.
  • The incidence of cholangiocarcinoma is increasing, but the exact reasons for this increase are not entirely clear.
  • Kevin Wemyss's biopsy confirmed the diagnosis in February.
  • The new targeted treatments being used in England have been shown to shrink tumors and prolong lives.

Sources:

  • Helen Puttick, "Denials of life-saving cancer treatments for over 200 Scots patients due to funding shortfall".
  • Cancer Research UK.
  • Scotttish NHS.
  • Jenni Minto, Scottish public health minister.
  • Kevin Wemyss, Lisa Wemyss (his wife).
  • Tim Kendall, liver pathologist at Edinburgh Royal Infirmary.